SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and downward pressure as investors react to a weak sales outlook, with the community actively debating whether the company's turnaround efforts are failing against mounting competition and structural brand decline. Discussion is polarized between those viewing current levels as a long-term value opportunity and those calling for further drops due to concerns over inventory, geopolitical headwinds, and a perceived loss of market relevance.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as investors weigh an upcoming earnings report against the backdrop of broader cannabis sector volatility, with community debate sharply divided between those betting on a potential post-earnings rally or short squeeze and those citing concerns over dilution and management performance.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the company's long-term potential in AI infrastructure against broader market pressure from geopolitical instability in the Middle East. While bulls highlight upcoming earnings and expectations for new hyperscaler lease agreements as catalysts for a rebound, the stock is facing heavy selling pressure that has the community divided between those aggressively buying the dip and those concerned about the lack of immediate upward momentum.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is currently the subject of intense debate among investors as they weigh the company's long-term potential in the voice AI sector against persistent bearish sentiment and recent downward price pressure. The community is actively tracking high short interest and institutional buying patterns, with many traders looking for a potential squeeze catalyst while others remain cautious due to ongoing macroeconomic and geopolitical volatility.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is generating intense buzz following its debut as a pure-play space economy fund featuring significant direct exposure to SpaceX. While some traders view the ETF as an accessible, high-volatility opportunity to gain exposure to private space assets, skeptics are actively debating the fund's low assets under management and the transparency of its underlying holdings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are heavily debating the sustainability of the semiconductor sector's parabolic run, with many actively trading SOXS to hedge against potential instability and potential cooling in AI-related spending. The community remains divided, as some continue to build short positions expecting a correction, while others caution that the sector's resilience in the face of geopolitical tension makes it a dangerous 'widowmaker' for those betting against it.

BARK, Inc. is a dog-centric company, engaged in making products, services, and content for dogs. It operates through the Direct to Consumer and Commerce segments. The Direct to Consumer segment is composed of subscription-based products delivered on a monthly basis. The Commerce segment refers to the sale of BARK products in retail stores and other e-tailers. The company was founded by Matt M. Meeker, Henrik Werdelin, and Carly Strife in 2012 and is headquartered in New York, NY.

BARK Inc - Ordinary Shares - Class A

BARK Inc

BARK is seeing heightened activity as investors weigh the company's recent debt-free status and cost-cutting measures against the upcoming 1-for-20 reverse stock split intended to regain NYSE compliance. While some in the community view the split as a necessary survival step to attract institutional interest, others are skeptical, with active discussions focusing on the potential for volatility, short interest dynamics, and the contrast between current valuation and historical performance.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as the community monitors its upcoming 10-K filing and earnings, with investors focused on significant debt reduction, restored Nasdaq compliance, and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high, with many users highlighting the stock's potential for a valuation re-rating, despite ongoing pressure from short interest and market volatility.

Target Hospitality Corp. engages in the provision of rental accommodation with catering and hospitality services. It operates through the following business segments: HFS South, Government, and All Other. The HFS South segment consists primarily of rental and vertically integrated hospitality services revenue from customers in the natural resources and development industry located primarily in Texas and New Mexico. The Government segment is involved in rental and vertically integrated hospitality services revenue from customers with Government contracts in Texas. The All Other segment focuses on rental and vertically integrated hospitality services revenue from customers primarily in the natural resources and development industry located outside of the HFS South segment. The company was founded by Brian Scott Lash in 1978 and is headquartered in The Woodlands, TX.

Target Hospitality Corp - Ordinary Shares - Class A

Target Hospitality is trending following a massive $550 million contract win to support a major data center hub, sparking community excitement over the company's strategic pivot into AI and hyperscaler infrastructure. Investors are actively debating the stock's potential as a key play on the broader industrial and energy buildout, while monitoring momentum and analyst upgrades to determine if this growth is sustainable.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors closely monitor the FDA's timeline for the sNDA filing of AXS-05 for Alzheimer's disease agitation. The community is actively discussing the stock's recent price action at all-time highs while awaiting formal notification regarding the agency's review status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS...

Why Biogen Stock Sank While the Market Soared on Thursday

Key PointsIf all goes as planned, it'll soon be the owner of Apellis Pharmaceuticals...

Biogen (NASDAQ:BIIB) Shares Gap Down - Here's Why

Biogen (NASDAQ:BIIB) Shares Gap Down - Time to Sell...

Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza

BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.

Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal

Apellis surges after Biogen's $5.6 billion buyout at $41 per share, adding complement therapies and boosting long-term EPS outlook.read more...

Biogen Details $5.6B Apellis Deal, Sees Mid-to-High-Teens Growth and EPS Accretion by 2027

Biogen (NASDAQ:BIIB) executives outlined their rationale and financial expectations for a proposed acquisition of Apellis during a business update call, positioning the deal as a way to add near-term...

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave...

Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout

Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout

 Futures are higher on a WSJ report that Trump is considering exiting the middle east conflict even if the Strait of Hormuz is not reopened; but the market is deciding whether this is a genuine intent to...

Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio

Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio ?of rare-disease medicines...

<ul class="summary-bullets"><li>Biogen stated Apellis shareholders will also receive two contingent value rights as part of the all-cash deal.</li><li>This entitles Apellis shareholders to receive two payments of $2 per share, contingent on Syfovre meeting certain annual global net sales thresholds.</li><li>Biogen stated that the Apellis acquisition will add two commercialized medicines in differentiated immunology and rare diseases to its growth portfolio: Empaveli and Syfovre.</li></ul>Apellis Pharmaceuticals Inc. (APLS) shares soared 140% in Tuesday’s pre-market trade after Biogen Inc. (BIIB) announced that it has agreed to acquire the company in a $5.6 billion deal.Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis Pharmaceuticals</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/APLS">Biogen shares</a> were down nearly 3% at the time of writing.Biogen stated that Apellis shareholders will also receive two contingent value rights (CVRs) as part of the all-cash deal, entitling the holder to receive two payments of $2 per share, contingent on certain annual global net sales thresholds for Syfovre being met.<h2 class="st-heading-2">What Does Apellis Bring To The Table?</h2>Biogen stated that the Apellis acquisition will add two commercialized medicines in differentiated immunology and rare diseases to its growth portfolio: Empaveli and Syfovre.Syfovre is the first and only FDA-approved therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The regulator approved Empaveli in 2025 as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 years and older.<h2 class="st-heading-2">Biogen Highlights Revenue, Earnings Boost From Apellis Acquisition</h2>Biogen stated that Empaveli and Syfovre will boost its topline immediately, noting that these two treatments achieved combined net sales of $689 million in 2025 and expect them to grow in the mid-to-high teens at least through 2028.“Consistent with our strategy, this acquisition immediately advances Biogen’s ongoing transformation. The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio and bolsters our near-and long-term growth potential,” said Biogen CEO Christopher A. Viehbacher.The company added that the Apellis acquisition is expected to be increasingly accretive to Biogen’s diluted earnings per share (EPS) starting in 2027. Biogen stated that it plans to update the full-year 2026 guidance when it reports its first-quarter (Q1) earnings.<a href="https://stocktwits.com/symbol/APLS">APLS stock</a> is down 32% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> is up 7%. The S&amp;P Biotech ETF (XBI) is up 41% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF (VB) is up 15%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artl-bfrg-hkit-stocks-top-premarket-gainers-march-31-2026/cZEPAT9RIV2">ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen

Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.

Equity

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$3.04	--	--	N/A
Q4 '25	$1.63	$1.99	22.45%	BEAT
Q3 '25	$3.88	$4.81	23.89%	BEAT
Q2 '25	$3.90	$5.47	40.38%	BEAT
Q1 '25	$2.90	$3.02	4.16%	BEAT

BIIB
Biogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest BIIB News

BIIBBiogen Inc